Oncology: Treatment Options for Hematologic Malignancies (Audio-Digest Foundation Oncology Continuing Medical Education (CME).)

Closer Look
				Released: 2012-06-11 Released: 2012-06-11
		Lowest New Price: Click Here
		Pages: 19 Format: Kindle Edition

Also Shop International: (Not all items available internationally)
        

Oncology: Treatment Options for Hematologic Malignancies (Audio-Digest Foundation Oncology Continuing Medical Education (CME).) Editorial Review:
Purpose: Audio-Digest Foundation CME/CE activities are designed to provide its learners – physicians and other healthcare professionals – with continuing education that will help identify clinical problems in their practice settings, provide content to help to solve those problems, and increase their application of knowledge to practice.

Audio-Digest Oncology is specifically designed to provide the participant with up-to-date and accurate information on areas of competency as identified by the ABIM Medical Oncology MOC Examination Blueprint and ASCO's Core Curriculum Outline. Topics include, but are not limited to, the following:

The 37 cancer types and sites
Treatment regimens and methods, including chemotherapy, radiation therapy, hormonal therapies, and biological response modifiers
Other treatment-related issues, including oncological emergencies, paraneoplastic syndrome, bone marrow transplantation, local therapy of metastatic cancers, and management of malignant effusions
Complications, including infections and other complications of treatment; effects of disease and treatment on the patient, including psychosocial and psychological issues
Supportive care, including pain management, hematopoietic growth factors, transfusion therapy,nutritional support, end-of-life care, etc.
Procedures, including chemotherapy administrations, tumor assessment, bone marrow aspiration, biopsy and interpretation
Geriatric oncology

The goal of this program is to improve the management of hematologic malignancies. After hearing and assimilating this program, the clinician will be better able to:

1: Compare the efficacy of second-generation tyrosine kinase inhibitors (TKIs) to first generation imatinib for the treatment of chronic myeloid leukemia (CML).

2: Evaluate the evidence supporting the addition of TKIs to standard chemotherapy for the treatment of acute lymphocytic leukemia.

3: Explain the clinical and molecular aspects of fludarabine-refractory chronic lymphocytic leukemia (CLL).

4: Assess the benefits and risks of newer therapies for high-risk and ultra-high-risk CLL.

5: Recognize the effect of genetic mutations on the evaluation and treatment of hematologic malignancies.

Related Categories:
>> >>Cancer >>Oncology >> >> >>Chemotherapy